Jubilant Pharma Limited has recently announced that it has successfully completed safety and pharmacokinetic/absorption studies in animals and healthy human volunteers in India using a novel oral drug formulation of Remdesivir in comparison to the commercially available injectable formulation of Remdesivir.
The company has sought authorization for additional studies for this novel oral formulation from the Drug Controller General of India (DCGI).
